Taro Pharmaceutical Industries Ltd. (TARO): Price and Financial Metrics
TARO Price/Volume Stats
| Current price | $42.97 | 52-week high | $45.76 |
| Prev. close | $42.97 | 52-week low | $32.67 |
| Day low | $42.89 | Volume | 242,100 |
| Day high | $42.98 | Avg. volume | 45,199 |
| 50-day MA | $42.50 | Dividend yield | N/A |
| 200-day MA | $40.20 | Market Cap | 1.62B |
TARO Stock Price Chart Interactive Chart >
Taro Pharmaceutical Industries Ltd. (TARO) Company Bio
Taro Pharmaceutical Industries offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company was founded in 1959 and is based in Haifa Bay, Israel.
Latest TARO News From Around the Web
Below are the latest news stories about TARO PHARMACEUTICAL INDUSTRIES LTD that investors may wish to consider to help them evaluate TARO as an investment opportunity.
Iovance (IOVA) Falls After Clinical Update on Lung Cancer DrugIovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines. |
Senti Bio (SNTI) Rises as FDA Clears IND for Cancer CandidateThe FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises. |
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive CandidiasisCidara's (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%. |
Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer ProgramSanofi (SNY) stops the development of tusamitamab ravtansine after a phase III study on the candidate for second-line metastatic non-small cell lung cancer fails to meet the primary endpoint. |
Taro Provides Results for September 30, 2023HAWTHORNE, N.Y., October 26, 2023--TARO PROVIDES RESULTS FOR SEPTEMBER 30, 2023 |
TARO Price Returns
| 1-mo | N/A |
| 3-mo | 0.54% |
| 6-mo | 1.97% |
| 1-year | 12.28% |
| 3-year | -38.25% |
| 5-year | -47.33% |
| YTD | 2.85% |
| 2023 | 43.87% |
| 2022 | -42.05% |
| 2021 | -31.75% |
| 2020 | -16.50% |
| 2019 | 3.89% |
Continue Researching TARO
Want to see what other sources are saying about Taro Pharmaceutical Industries Ltd's financials and stock price? Try the links below:Taro Pharmaceutical Industries Ltd (TARO) Stock Price | Nasdaq
Taro Pharmaceutical Industries Ltd (TARO) Stock Quote, History and News - Yahoo Finance
Taro Pharmaceutical Industries Ltd (TARO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...